The use of Azilsartan in patients with post-operation of Radiofrequency ablation in AF

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069585

Enrollment

Unknown

Registered

2023-03-21

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Azilsartan group:Oral Azilsartan

Candesartan:Oral Candestan

Not taking any ACEI/ARB group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age 18 years or older;2.Agreed to participate in the trial and signed an informed consent form;3.AF Radiofrequency ablation after admission;4.A definite diagnosis of hypertension;5.a definite history of paroxysmal or persistent AF.

Exclusion criteria

Exclusion criteria: 1.Life Expectancy less than 1 year;2. Atrial fibrillation due to rheumatic valvular heart disease;3. Atrial fibrillation due to postoperative cardiac surgery; 4.Patients with unilateral or bilateral renal artery stenosis;5. Evidence of severe pulmonary hypertension (PASP more than GT; 70mmHg) 6. The investigators considered the subjects unfit to participate in this trial.

Design outcomes

Primary

Measure	Time frame
Color Doppler ultrasound of the heart;left atrial size;degree of valve regurgitation;peak E/peak A ratio;EDV/ESV ratio;	—

Countries

China

Contacts

Public ContactRui Yan

Shanxi Provincial Hospital of cardiovascular diseases

yanrui198309@163.com15934041121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026